vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2018-3-70-74vtio-914Research ArticleКлинические наблюденияClinical CasesКонверсия на эверолимус с целью сохранения функции почек при трансплантации сердца, персонализированный подход при выборе иммуносупрессивной терапииConversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapyКолосковаН. Н.KoloskovaN. N.

Адрес: 123182, Москва, ул. Щукинская, д. 1. Тел. (926) 651-40-64

Address: 1, Shchukinskaya st., Moscow, 123182, Russian Federation. Теl. (926) 651-40-64

nkrasotka@mail.ruНикитинаЕ. А.NikitinaE. A.ЗахаревичВ. М.ZakharevichV. M.МуминовИ. И.MuminovI. I.КванВ. С.CvanV. S.ПопцовВ. Н.PoptsovV. N.АхмадзайР. Л.AhmadzaiR. L.ИзотовД. А.IzotovD. A.ШевченкоА. О.ShevchenkoA. O.ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationRussian FederationФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)Russian Federation2018160920182037074Copyright © Колоскова Н.Н., Никитина Е.А., Захаревич В.М., Муминов И.И., Кван В.С., Попцов В.Н., Ахмадзай Р.Л., Изотов Д.А., Шевченко А.О., 20182018Колоскова Н.Н., Никитина Е.А., Захаревич В.М., Муминов И.И., Кван В.С., Попцов В.Н., Ахмадзай Р.Л., Изотов Д.А., Шевченко А.О.Koloskova N.N., Nikitina E.A., Zakharevich V.M., Muminov I.I., Cvan V.S., Poptsov V.N., Ahmadzai R.L., Izotov D.A., Shevchenko A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/914

На сегодняшний день трансплантация сердца остается «золотым стандартом» лечения терминальной стадии хронической сердечной недостаточности. Выживаемость пациентов после трансплантации сердца значительно улучшилась с момента внедрения в клиническую практику ингибиторов кальциневрина (CNI). Однако отдаленные результаты выживаемости ограничены,  что обусловлено развитием побочных эффектов на фоне длительного приема  иммуносупрессивной терапии. Нефротоксичность, обусловленная длительным приемом  ингибиторов кальциневрина, приводит к нарушению функции почек с развитием почечной  недостаточности, что ухудшает прогноз у реципиентов в отдаленном периоде. Применение сертикана в схемах иммуносупрессивной терапии позволяет редуцировать дозу ингибиторов  кальциневрина, тем самым оказывая положительное влияние на почечную функцию у  реципиентов после трансплантации сердца. Цель нашего сообщения: продемонстрировать  успешный случай конверсии на эверолимус у реципиента после трансплантации сердца и оценить эффективность использования данного препарата в течение года наблюдения.

Heart transplantation is the «gold standard» of treatment severe heart failure. Patient survival after heart transplantation has improved dramatically since the  availability of calcineurin inhibitor (CNIs). However, nephrotoxicity of CNIs has been  largely responsible for the progressive development of renal dysfunction and  reduces long-term patient survival. Use mTOR inhibitor in immunosuppressive  therapy may improve renal function when everolimus is administered associated  with a progressive reduction of CNIs. The purpose of our report is to demonstrate  the successful case of conversion of the recipient after heart transplantation to  everolimus and to evaluate the effectiveness of this drug during the observation year after heart transplantation.

трансплантация сердцаиммуносупрессивная терапиянефротоксичность ингибиторов калициневринапочечная недостаточностьэверолимусmTOR-ингибиторыheart transplantationimmunosuppressive therapynephrotoxicity of calcineurin inhibitorrenal dysfunctionеverolimusmTOR inhibitorReferencesLund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report – 2014; focus theme: retransplantation. J. Heart Lung Transplant. 2014; 33: 996–1008.Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report – 2014; focus theme: retransplantation. J. Heart Lung Transplant. 2014; 33: 996–1008.Manito N, Delgado JF, Crespo-Leiro MG, Arizón JM, Segovia J, González-Vílchez F et al. Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. World J. Transplant. 2015 Dec. 24; 5 (4): 310–319.Manito N, Delgado JF, Crespo-Leiro MG, Arizón JM, Segovia J, González-Vílchez F et al. Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. World J. Transplant. 2015 Dec. 24; 5 (4): 310–319.The registry of the international society for heart and lung transplantation: thirty- second annual report – 2017. JHLT. 2017 Oct; 36 (10): 1037–1079.The registry of the international society for heart and lung transplantation: thirty- second annual report – 2017. JHLT. 2017 Oct; 36 (10): 1037–1079.Готье СВ. Иммуносупрессия при трансплантации солидных органов. М.: Триада, 2011: 12–17. Gautier SV. Immunosupressiya pri transplantatsii solidnykh organov. M.: Triada, 2011: 12–17.Готье СВ. Иммуносупрессия при трансплантации солидных органов. М.: Триада, 2011: 12–17. Gautier SV. Immunosupressiya pri transplantatsii solidnykh organov. M.: Triada, 2011: 12–17.Kobashigawa J.A., Pauly D., Kfoury A et al. Multicenter randomized trial of everolimus vs mycophenolate mofetil in heart transplantation: final 24 month analysis of efficacy and safety. J. Heart Lung Transplant. 2012; 31: S73–S74.Kobashigawa J.A., Pauly D., Kfoury A et al. Multicenter randomized trial of everolimus vs mycophenolate mofetil in heart transplantation: final 24 month analysis of efficacy and safety. J. Heart Lung Transplant. 2012; 31: S73–S74.González-Vílchez F, Vazquez de Prada JA, Paniagua MJ, Gomez-Bueno M, Arizon JM, Almenar L et al. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Int. J. Cardiol. 2014; 171: 15– 23.González-Vílchez F, Vazquez de Prada JA, Paniagua MJ, Gomez-Bueno M, Arizon JM, Almenar L et al. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Int. J. Cardiol. 2014; 171: 15– 23.Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. 1984; 311: 699–705. [PubMed] 22. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant. Proc. 2004; 36: 234S–239S.Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. 1984; 311: 699–705. [PubMed] 22. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant. Proc. 2004; 36: 234S–239S.Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89: 864–872.Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89: 864–872.Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation. 2010; 90: 1581–1589.Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation. 2010; 90: 1581–1589.Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J. Heart Lung Transplant. 2005; 24: 196.Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J. Heart Lung Transplant. 2005; 24: 196.Bocchi EA, Ahualli L, Amuchastegui M et al. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. Transplant. Proc. 2006; 38: 937.Bocchi EA, Ahualli L, Amuchastegui M et al. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. Transplant. Proc. 2006; 38: 937.Lehmkuhl H, Ross H, Eisen H et al. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant. Proc. 2005; 37: 4145.Lehmkuhl H, Ross H, Eisen H et al. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant. Proc. 2005; 37: 4145.Fiocchi R, Frigerio M, Parisi F et al. Guidelines for everolimus introduction in stable heart transplant. Trapianti. 2006; 3: 107.Fiocchi R, Frigerio M, Parisi F et al. Guidelines for everolimus introduction in stable heart transplant. Trapianti. 2006; 3: 107.Kuypers DRJ, Le Meur Ya, Cantarovich M et al. The Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clin. J. Am. Soc. Nephrol. 2010; 5: 341–358.Kuypers DRJ, Le Meur Ya, Cantarovich M et al. The Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clin. J. Am. Soc. Nephrol. 2010; 5: 341–358.Mohammadpour N, Elyasi S, Vahdati N. A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs. Iranian Journal of Basic Medical Sciences. 2011; 14 (6): 485–498.Mohammadpour N, Elyasi S, Vahdati N. A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs. Iranian Journal of Basic Medical Sciences. 2011; 14 (6): 485–498.

The authors declare that there are no conflicts of interest present.